FUJIREBIO DIAGNOSTICS CA 19-9 RIA

{0}------------------------------------------------ MAY 0 9 2002 Image /page/0/Picture/1 description: The image shows the logo for "FUJIREBIO DIAGNOSTICS, INC." The logo consists of a stylized graphic to the left of the text. To the right of the text is a handwritten number, "K020566". ## 510(k) SUMMARY This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: K020566. ### Submitter Information | Address: | Fujirebio Diagnostics, Inc.<br>201 Great Valley Parkway<br>Malvern, PA 19355 | |---------------------------|---------------------------------------------------------------------------------| | Contact person: | Daniel J. O'Shannessy, Ph.D., (610) 240-3811 | | Summary preparation date: | February 15, 2002 | | Name of Device | | | Trade/Proprietary Name: | Fujirebio Diagnostics CA 19-9TM RIA | | Common/Usual Name: | Immunological test for 1116NS19-9 Antibody Defined Antigen<br>(CA 19-9) | | Classification Name: | 21CFR 866.6010, Class II, Tumor Associated Antigen<br>Immunological Test System | | Predicate Device | | Abbott Laboratories AxSYM® CEA MEIA ### Device Description The Fujirebio Diagnostics CA 19-9™ RIA is a solid-phase radioimmunoassay based on the forward sandwich principle. Polystyrene beads coated with a mouse monoclonal antibody against CA 19-9 are incubated with a serum or plasma specimen, or the appropriate standards or controls. During the incubation, the CA 19-9 antigen present in the specimen is specifically bound to the solid support by the mouse monoclonal antibody. Unbound material present in the specimen is removed by aspiration and washing of the beads. The same mouse monoclonal anti-CA 19-9 labeled with 1281 is then incubated with the beads and binds {1}------------------------------------------------ to the CA 19-9 antigen already bound to the beads. Unbound labeled antibody is removed by aspiration and washing. The bound radioactivity is determined by counting the beads in a gamma counter. A standard curve is obtained by plotting the CA 19-9 antigen concentration of the standards versus bound radioactivity. The CA 19-9 antigen concentrations of unknown patient specimens are determined from the standard curve and are directly proportional to the concentration of the bound tracer molecules. #### Intended Use The Fujirebio Diagnostics CA 19-9™ RIA, an in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen, in human serum or plasma, is indicated for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in: Monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of serum or plasma CA 19-9 above the cutoff, at the time of diagnosis. CA 19-9 values must be interpreted in conjunction with all other available clinical and laboratory data before a medical decision is determined. #### Summary of Performance characteristics #### Analytical Sensitivity (Minimal Detectable Dose) The analytical sensitivity was determined to be 0.9 U/mL. This level of analytical sensitivity is well below the established "cut-off" of 37 U/mL. #### Interfering Substances The appropriate NCCLS guideline was followed to determine possible sources of interference with the Fujirebio Diagnostics CA 19-9™ RIA kit. Only human anti-mouse antibodies (HAMA), at a titer of 16,636, showed potential interference with the assay. This concentration of human anti-mouse antibody is extremely high. HAMA was also tested at a lower titer of 1664 and showed no effect on the assay. All other substances that were tested with the Fujirebio Diagnostics CA 19-9™ RIA kit showed no interference at the levels tested. #### Recoverv Studies Ten (10) patient samples were spiked with purified CA 19-9 antigen at three (3) different levels. Results were reported as percent recoveries (% Recovery) and compared to the acceptable percent Recovery Limits calculated using the precision of the assay diluent buffer (which was run as samples, both spiked and unspiked). For the Low spike samples, where the values of added antigen were approximately 8 U/mL, acceptable limits of % Recovery were calculated as being 87.9 - 112.1%. For the Mid spike samples, where the values of added antigen were approximately 29 U/mL, acceptable limits of % Recovery were calculated to be 81.9 - 118%. For the High spike samples, where the values of added antigen were approximately 90 U/mL, acceptable limits of % Recovery were calculated to be 93.0 - 107.0%. These data are listed in the table below. {2}------------------------------------------------ | Patient<br>Number | Low Spike<br>Percent Recovery | Mid - Spike<br>Percent Recovery | High Spike<br>Percent Recovery | |-------------------|-------------------------------|---------------------------------|--------------------------------| | 1 | 110.23% | 103.42% | 111.58% | | 2 | 112.12% | 101.87% | 96.49% | | 3 | 114.08% | 102.35% | 99.07% | | 4 | 121.37% | 102.30% | 107.50% | | 5 | 112.41% | 102.89% | 100.45% | | 6 | 92.31% | 102.18% | 99.99% | | 7 | 117.43% | 100.93% | 98.81% | | 8 | 101.98% | 97.75% | 99.10% | | 9 | 99.64% | 102.43% | 98.49% | | 10 | 101.78% | 102.96% | 99.78% | | Mean | 108.34% | 101.91% | 101.13% | #### Linearity The linearity of the Fujirebio Diagnostics CA 19-9 RIA was tested with serial dilutions of 12 individuals with elevated CA 19-9 assay values. Dilutions were prepared in CA 19-9 0 Standard/Diluent Regression analysis comparing observed and expected CA 19-9 assay values yielded a mean slope for the twelve samples of 0.96 ± 0.031 and a mean y-intercept of 5.97 ± 7.65. #### Reproducibility: Each of three (3) sites performed one (1) run per day for thirteen (13) acceptable days with three (3) different lots of product. Test materials were assayed in random order for each run. but were tested identically across each lot of reagent under evaluation. The total average variability ranged from 6.7% (44 U/mL) to 15.4% (8 U/mL). Day-to-day variation across sample-site-lot combinations peaked at 14.9 % CV with a nadir of 0%. The maximum intra-assay variation was 18 % at a CA 19-9 concentration of 8 U/mL, a concentration below the first non-zero calibrator and well under the clinical cut-off of 37 U/mL. The average intra-assay variation across all sites and lots for that 8 U/mL sample was 12.5 % CV. For all other concentrations tested, the average intra-assay variation did not exceed 6.5% CV. ### Clinical Data #### Apparently Healthy Subjects: To determine the distribution of CA 19-9 values in apparently normal healthy individuals, and to confirm the cutoff of 37 U/mL, a sample of 200 women and 200 men who were apparently disease free were assessed. {3}------------------------------------------------ ## Fujirebio Diagnostics CA 19-9™ RIA Distribution of | Group | Total | <37<br>U/mL | 37 - 49.9<br>U/mL | 50 - 69.9<br>U/mL | 70 - 99.9<br>U/mL | >100<br>U/mL | |---------|-------|-------------|-------------------|-------------------|-------------------|--------------| | Males | 200 | 189 (94.5%) | 4 (2.0%) | 5 (2.5%) | 0 (0.0%) | 2 (1.0%) | | Females | 200 | 186 (93.0%) | 7 (3.5%) | 4 (2.0%) | 2 (1.0%) | 1 (0.5%) | ## Values of Apparently Healthy Subjects ### Benign Disease Cohorts: Three hundred and ninety-nine (399) benign disease patient cohorts were assembled to determine the distribution of serum CA 19-9 values in benign diseases that may be coexistent in patients with confirmed pancreatic cancer. | Diagnostic Group | Total | <37<br>U/mL | 37 - 49.9<br>U/mL | 50 - 69.9<br>U/mL | 70 - 99.9<br>U/mL | ≥100<br>U/mL | |--------------------------------------------------|-------|-------------|-------------------|-------------------|-------------------|--------------| | Benign Diseases of the<br>Genitourinary Tract | 99 | 90 (90.9%) | 6 (6.1%) | 2 (2.0%) | 1 (1.0%) | 0 (0.0%) | | Benign Diseases of the<br>Gastrointestinal Tract | 100 | 88 (88.0%) | 7 (7.0%) | 3 (3.0%) | 2 (2.0%) | 0 (0.0%) | | Benign Diseases of the<br>Pancreas/Pancreatitis | 100 | 94 (94.0%) | 1 (1.0%) | 4 (4.0%) | 1 (1.0%) | 0 (0.0%) | | Chronic Heart Disease/<br>Hypertension | 100 | 80 (80.0%) | 10 (10.0%) | 5 (5.0%) | 5 (5.0%) | 0 (0.0%) | ### Fujirebio Diagnostics CA 19-9™ RIA Distribution of Values Benign Diseases #### Monitoring of Disease Status in Patients Diagnosed with Pancreatic Cancer: The effectiveness of CA 19-9 as an aid in monitoring of disease status in patients diagnosed with pancreatic cancer was determined by assessing changes in CA 19-9 levels in serial serum sets with changes in disease status. Samples from 61 patients with a total of 234 observations were analyzed. The average number of observations per patient was 3.84. Fifty-seven percent (57%) of the positive serum sets correlated with disease progression while seventy-one (71%) of serum sets showing no significant change in the marker correlated with no progression. The Table below presents the data in a 3x3 classification scheme. The disease states are: - Progression from one collection to the next collection (Progressing). . - No Change in disease status (Stable). . - Reduction in the signs and symptoms of the disease from one collection to the next . (Responding). Marker changes are classified as: {4}------------------------------------------------ - A 20% or greater increase in the marker from one collection to the next (INC) . - No significant change in the marker (|Delta CA 19-9|<20%) (NC) . - A 20% or greater decrease in the marker value from one collection to the next (DEC) . ## Expanded Distribution | Marker<br>Change | Disease Status | | | Total | |------------------|----------------|--------------|--------------|-------| | | Progressive | Stable | Responding | | | INC | 31 | 30 | 4 | 65 | | | 56.4% (1.29) | 32.3% (.477) | 16.0% (.190) | 37.6% | | NC | 12 | 41 | 7 | 60 | | | 21.8% (.279) | 44.1% (.789) | 28.0% (.389) | 34.7% | | DEC | 12 | 22 | 14 | 48 | | | 21.8% (.279) | 23.7% (.310) | 56.0% (1.27) | 27.7% | | Total | 55 | 93 | 25 | 173 | {5}------------------------------------------------ Image /page/5/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three heads, representing the department's mission to protect the health of all Americans and provide essential human services. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle image. MAY 0 9 2002 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Daniel J. O'Shannessy, Ph.D. Chief Scientific Officer Fujirebio Diagnostics, Inc. 201 Great Valley Parkway Malvern, Pennsylvania 19355-1307 Re: k020566 > Trade/Device Name: Fujirebio Diagnostics CA 19-9TM RIA Regulation Number: 21 CFR § 866.6010 Regulation Name: Tumor Associated antigen Immunological Test System Regulatory Class: II Product Code: NIG Dated: April 19, 2002 Received: April 23, 2002 Dear Dr. O'Shannessy: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {6}------------------------------------------------ Page 2 This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed nvellicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Butman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {7}------------------------------------------------ ## INDICATIONS FOR USE STATEMENT Page 1 of 510(k) Number (if known): K020566 # Device Name: Fujirebio Diagnostics CA 19-9™ RIA The Fujirebio Diagnostics CA 19-9™ RIA, an in vitro diagnostic test for the quantitative The Tullion Diagnootio Cr. To associated antigen, in human serum or plasma, is indicated measurement of the OF 10 Claims. 18-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in: Monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of serum or plasma CA 19-9 above the cutoff, at the time of diagnosis. CA 19-9 values must be interpreted in conjunction with all other available clinical and laboratory data before a medical decision is determined. Sousan S. Altaie (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number K020566 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurence of CDRH, Office of Device Evaulation (ODE) (Optional Format 3-10-98)